Ocugen Is Maintained at Buy by Chardan Capital

Ocugen Is Maintained at Buy by Chardan Capital

Dow JonesMay 15 11:08 ET

4 Analysts Assess Ocugen: What You Need To Know

4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent rating

BenzingaMay 15 08:01 ET

Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study

Ocugen (OCGN) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time tre

MT NewswiresMay 15 07:30 ET

Express News | HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target

BenzingaMay 15 06:45 ET

Ocugen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/22/2024 197.62% Chardan Capital $4 → $

BenzingaMay 15 06:44 ET

Buy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical Pipeline

TipRanksMay 15 06:36 ET